Company intelligence / Profile preview

Mginbio

Seoul, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

MGinBio is a South Korean biotechnology company specializing in the development of next-generation gene therapies using Adeno-Associated Virus (AAV) and mRNA technologies. Founded in 2018, the company focuses on treating rare genetic disorders and chronic diseases with high unmet medical needs, such as Hemophilia A and Fabry disease. MGinBio utilizes its proprietary MG-AAV platform to enhance the safety and efficacy of viral vector delivery. The company is actively advancing its pipeline through pre-clinical studies and aims to transition into clinical-stage development through rigorous R&D and strategic collaborations.

Therapeutic areas: HematologyRare Diseases
Modalities: Gene therapymRNA-based drugs
Industry: Biotech

Beyond the preview

Go deeper on Mginbio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mginbio.

Explore the full profile